Nevanac 3-Month Safety Study With QID Dosing

Last updated: March 1, 2012
Sponsor: Alcon Research
Overall Status: Completed

Phase

3

Condition

Vision Loss

Eye Disorders/infections

Eye Disease

Treatment

N/A

Clinical Study ID

NCT00332774
C-05-20
  • Ages > 10
  • All Genders

Study Summary

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients of any race or sex ages 10 years or older undergoing cataract extraction withplanned implantation of a posterior chamber intraocular lens.

  • Other protocol-defined inclusion criteria may apply.

Exclusion

Exclusion Criteria:

  • Under 10

  • Other protocol-defined exclusion criteria may apply

Study Design

Total Participants: 149
Study Start date:
February 01, 2006
Estimated Completion Date:
December 31, 2006

Connect with a study center

  • Contact Alcon for Trial Locations

    Fort Worth, Texas 76134
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.